JP2023522676A5 - - Google Patents

Info

Publication number
JP2023522676A5
JP2023522676A5 JP2022563172A JP2022563172A JP2023522676A5 JP 2023522676 A5 JP2023522676 A5 JP 2023522676A5 JP 2022563172 A JP2022563172 A JP 2022563172A JP 2022563172 A JP2022563172 A JP 2022563172A JP 2023522676 A5 JP2023522676 A5 JP 2023522676A5
Authority
JP
Japan
Prior art keywords
seq
sequence number
polypeptide
less
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022563172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522676A (ja
JP7821741B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028679 external-priority patent/WO2021216899A1/en
Publication of JP2023522676A publication Critical patent/JP2023522676A/ja
Publication of JP2023522676A5 publication Critical patent/JP2023522676A5/ja
Application granted granted Critical
Publication of JP7821741B2 publication Critical patent/JP7821741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022563172A 2020-04-22 2021-04-22 動物用のｉｌ４／ｉｌ１３受容体分子 Active JP7821741B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063014090P 2020-04-22 2020-04-22
US63/014,090 2020-04-22
US202063014573P 2020-04-23 2020-04-23
US63/014,573 2020-04-23
PCT/US2021/028679 WO2021216899A1 (en) 2020-04-22 2021-04-22 Il4/il13 receptor molecules for veterinary use

Publications (3)

Publication Number Publication Date
JP2023522676A JP2023522676A (ja) 2023-05-31
JP2023522676A5 true JP2023522676A5 (enExample) 2024-05-02
JP7821741B2 JP7821741B2 (ja) 2026-02-27

Family

ID=78270112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563172A Active JP7821741B2 (ja) 2020-04-22 2021-04-22 動物用のｉｌ４／ｉｌ１３受容体分子

Country Status (10)

Country Link
US (1) US20240270819A1 (enExample)
EP (1) EP4139344A4 (enExample)
JP (1) JP7821741B2 (enExample)
KR (1) KR20230005880A (enExample)
CN (1) CN116034112A (enExample)
AU (1) AU2021259785A1 (enExample)
BR (1) BR112022021204A2 (enExample)
CA (1) CA3173927A1 (enExample)
MX (1) MX2022013149A (enExample)
WO (1) WO2021216899A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
JP7657548B2 (ja) 2017-04-21 2025-04-07 エランコ・ユーエス・インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
EP3870601A4 (en) 2018-10-25 2022-07-13 Kindred Biosciences, Inc. IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
WO2025141037A1 (en) * 2023-12-28 2025-07-03 Elanco Animal Health Gmbh Il-4/il-13 and il-4/il-13/il-31 receptor trap constructs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023289A1 (en) * 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
MX361174B (es) * 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
WO2005085284A1 (en) * 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 sepecific polypetides and therapeutic uses thereof
EP2596802A1 (en) * 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
US20170290889A1 (en) * 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
EP3481413A4 (en) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP3526246A1 (en) * 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
JP7657548B2 (ja) * 2017-04-21 2025-04-07 エランコ・ユーエス・インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
KR20250137204A (ko) * 2022-12-27 2025-09-17 인베티엑스 인코포레이티드 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법
AU2023415535A1 (en) * 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use

Similar Documents

Publication Publication Date Title
JP2025093964A (ja) 獣医学的使用のための、新生仔ｆｃ受容体（ｆｃｒｎ）への結合性が変化したｆｃ変異体
CN110382529B (zh) 工程化的异源二聚体蛋白质
JP2020517262A5 (enExample)
Jendeberg et al. Engineering of Fc1 and Fc3 from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A
Silacci et al. Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency
KR102132997B1 (ko) Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
JP2024026255A5 (enExample)
IL276286B1 (en) FC variants with improved binding to FCRN and extended half-life
Paudyal et al. Fc-mediated functions of porcine IgG subclasses
CN101704879A (zh) 具有改进的特异性的新型免疫球蛋白结合蛋白
CN110573626B (zh) 抗体选择方法
JP2005046146A5 (enExample)
Patel et al. Sequence of the dog immunoglobulin alpha and epsilon constant region genes
CN108290928B (zh) 卷曲螺旋连接体
JP7411264B2 (ja) 新規抗ｐａｄ２抗体
JP2023524643A5 (enExample)
CN116034112A (zh) 兽用il4/il13受体分子
KR20250057131A (ko) 수의학 용도를 위한 il4/il13 수용체 분자
JP2024507693A (ja) 二重特異性抗体
Taylor et al. Avian IgY binds to a monocyte receptor with IgG-like kinetics despite an IgE-like structure
Noble et al. Distinct effector functions mediated by Fc regions of bovine IgG subclasses and their interaction with Fc gamma receptors
JP2024531346A5 (enExample)
JP2023109920A (ja) 抗体ＦｃＲｎ結合の改変
RU2009126545A (ru) МУЛЬТИМЕРНЫЕ ПОЛИПЕПТИДЫ Fc-РЕЦЕПТОРА, ВКЛЮЧАЮЩИЕ МОДИФИЦИРОВАННЫЙ Fc-ДОМЕН
JP2019172702A (ja) 目的とする含量で不純物を含むＴＮＦＲ−Ｆｃ融合タンパク質の製造方法